

**Supplemental Table 1.** Patient Characteristics

Patient No.	Sex	Age (y)	Pathology	Findings	Therapy	TCD (GBq /Cycles)	Interval (d)	SUV Pre-therapy (g/ml)	SUV Post-therapy (g/ml)	Results
1	m	52	NET of pancreas	liver, bone	Y-90	13.4 / 4	90	71.2	60.1	MR
2	m	84	NET of colon	liver, bone, lymph node	Lu-177	6 / 3	38	30.2	34.2	SD
3	m	63	NET of small bowel	liver, lymph node	Y-90	6.13 / 3	57	22.8	14.0	SD
4	m	61	NET unknown primary	liver, bone	Lu-177	34.86 / 6	75	38.5	18.9	SD
5	m	61	NET of pancreas	liver	Y-90	21.4 / 6	92	34.3	60.9	SD
6	m	59	Gastrinoma	liver, bone	Y-90	14.75 / 4	60	43.5	37.6	PD

7	m	48	NET of pancreas	liver, lymph node	Y-90	6.2 / 2	59	23.3	23.9	PD
8	f	55	NET of pancreas	liver, lymph node	Lu-177	29.3 / 4	71	54.8	7.7	PR
9	m	81	NET of pancreas	liver, bone, lymph node	Lu-177	35.5 / 4	117	94.0	18.0	PD
10	f	41	NET of pancreas	liver, lymph node	Y-90	12.79 / 4	111	9.8	5.0	SD
11	f	59	NET of small bowel	liver	Y-90	6 / 2	55	20.8	20.0	PD
12	m	57	NET of small bowel	liver, bone, lymph node	Lu-177	14.8 / 3	59	26.5	29.3	SD
13	m	47	NET of small bowel	liver	Lu-177	14.2 / 4	109	23.9	27.7	SD
14	f	76	Gastrinoma	liver, bone, lymph node	Y-90	10.1 / 5	116	41.6	29.1	PD
					Y-90+Lu-	13.1+5.8 /				
15	f	73	NET of pancreas	liver, lymph node	177	6+1	118	66.0	16.3	PR
16	m	64	NET of pancreas	liver	Y-90	14.4 / 4	95	98.3	68.9	PR

17	m	34	NET of pancreas	liver, lymph node	Y-90	12.3 / 4	87	33.4	29.4	PD
			NET unknown							
18	f	52	primary	liver	Y-90	12 / 6	57	33.5	43.3	SD
19	f	78	NET of small bowel	liver	Lu-177	27 / 4	34	18.9	17.7	PR
					Y-90+Lu-					
20	f	57	NET of small bowel	liver, bone	177	8.1+2.1 / 4+1	88	29.9	19.2	PD
21	m	73	Glomus tumor	neck	Lu-177	26.4 / 4	74	35.1	46.9	SD
			NET of radix							
22	m	50	mesenterica	liver, lymph node	Lu-177	30.15 / 4	90	14.6	18.1	SD
23	m	74	NET of lung	bone, lymph node	Y-90	14.96 / 4	97	29.0	6.4	SD
24	f	61	NET of lung	liver, lung, heart	Y-90	13.3 / 4	90	64.2	48.2	SD
25	m	74	NET unknown	liver, bone	Y-90	23.3 / 6	78	13.1	25.6	PD

primary										
26	m	62	NET of small bowel	lymph node	Y-90	11.1 / 4	69	23.8	21.9	SD
27	m	58	NET of small bowel	liver, bone, lymph node	Y-90	11.3 / 5	108	34.2	39.9	SD
28	m	61	NET of lung	lung, lymph node	Lu-177	23.6 / 3	93	18.0	9.0	MR
Dendritic reticulum craniopharyngeal, lymph										
29	m	44	cell sarcoma	node, bone	Lu-177	24.9 / 4	120	31.2	21.7	SD
30	f	63	NET of pancreas	liver	Y-90	12.9 / 5	91	33.2	31.8	PD
31	m	67	NET of rectum	liver	Lu-177	30.15 / 4	42	45.5	6.8	CR
32	f	62	NET of small bowel	bone, lymph node	Lu-177	22.66 / 4	75	24.3	26.3	SD
liver, lung, bone, lymph										
33	m	50	NET of small bowel	node	Lu-177	29.3 / 4	48	34.7	28.8	SD
34	f	49	NET of rectum	liver, lymph node	Lu-	8.05+14.6 /	73	52.5	n.a.	PR

					177+Y-90	1+4				
35	m	57	NET of small bowel	liver, bone, lymph node	Lu-177	23.98 / 4	47	30.5	18.5	SD
36	f	47	NET of pancreas	liver	Lu-177	29.42 / 4	90	20.8	27.0	SD
37	m	82	NET of small bowel	liver, lymph node	Y-90	10.55 / 5	63	34.0	10.6	PR
38	m	47	NET of small bowel	liver, lymph node, lung	Lu-177	27.86 / 4	57	6.5	9.6	SD
39	m	65	NET of lung	liver, bone	Y-90	16.3 / 4	52	41.1	51.4	PR
40	m	39	NET of pancreas	liver, bone, lymph node	Y-90	4.2 / 2	57	20.5	26.2	PD
41	f	68	Gastrinoma	liver, lymph node	Y-90	14.4 / 4	101	80.5	49.0	PR
42	f	64	NET of pancreas	liver, bone	Lu-177	26 / 4	71	54.1	8.8	SD
			NET unknown							
43	f	51	primary	liver, bone	Lu-177	30.55 / 5	68	27.3	27.4	PR

44	f	45	NET of small bowel	liver, bone, lymph node	Y-90	12.9 / 6	73	8.1	8.5	MR
45	m	47	NET of small bowel	liver, lymph node	Y-90	17.07 / 6	35	267.0	54.7	MR
46	m	59	NET of pancreas	lymph node	Lu-177	24.58 / 4	80	6.8	9.8	SD

---

NET, neuroendocrine tumor

Lu-177, <sup>177</sup>Lu-DOTA-TATE; Y-90, <sup>90</sup>Y-DOTA-TOC

TCD, total cumulative dose (GBq), in parentheses number of cycles

Time interval between last therapy and restaging

Results according to the reference standard: MR, minor response; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease